The neutralization epitopes of human and simian rotavirus protein VP7 were studied by producing six neutralizing monoclonal antibodies (N-MAbs) and using these N-MAbs to select antigenic mutants that resisted neutralization by the N-MAbs used for their selection. Cross-neutralization tests between the N-MAbs and the antibody-selected antigenic mutants identified one cross-reactive and five distinct serotype-specific neutralization epitopes which operationally overlapped one another and constituted a single antigenic site. In addition, the amino acid substitutions in human rotavirus VP7 that are responsible for the antigenic alterations in the mutants selected with anti-VP7 cross-reactive or serotype-specific N-MAbs were identified. All the amino acid substitutions in the antigenic mutants occurred in one of two variable regions: amino acids 87 to 101 and 208 to 221.
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Seven group A rotavirus (RV) serotypes have been established by cross-neutralization tests (13) . In addition, several new candidate group A RV serotypes have been described recently (3, 16) . Serotype specificity has been attributed mainly to an outer capsid protein, VP7, on the basis of analysis of reassortant viruses with various constellations of RNA segments (11, 14) and protein specificity of serotypespecific neutralizing monoclonal antibodies (N-MAbs) (4, 21) . VP7 is coded for by gene 8 or 9 depending on the RV strain (11, 14) . The nucleotide sequence of the VP7 gene of more than 20 RV strains of various serotypes has recently been determined. A comparative analysis of their deduced amino acid sequences revealed six discrete divergent regions (A to F) among different serotypes (9, lOa, 12, 19) : amino acids 39 to 50 (A), 87 to 101 (B), 120 to 130 (C), 143 to 152 (D), 208 to 221 (E), and 233 to 242 (F). Since these six regions were highly conserved within a given serotype, it was likely that some or all of them were responsible for defining the serotype specificity of RV. By selecting antigenic mutants of simian RV SA-11 (serotype 3) with serotype 3-specific N-MAbs, Dyall-Smith et al. (7) identified three regions, corresponding to B, D, and E above (i.e., amino acids 87 to 96, 145 to 150, and 211 to 223), as the antigenic sites involved in serotype-specific neutralization. They also suggested that regions B and E appeared to be in close proximity in the folded protein but widely spaced in the linear molecule (7) . In addition, the sequences of the B and E regions of a variety of reference and field strains have been shown to correlate absolutely with the serotype determined by standard immunologic methods such as neutralization (lOb).
We previously prepared five serotype 1-specific N-MAbs, designated KU-2, KU-4, KU-3C7, KU-5H1, and KU-6A11, directed to human RV (HRV) VP7 and used these antibodies to select four antigenic escape mutants (V-KU-4, V-KU-3C7, V-KU-5H1, and V-KU-6A11) of strain KU (serotype 1); each of the N-MAb escape mutants was resistant to neutralization by the antibody used for its selection (17a) . Analysis of the five N-MAbs and the four escape mutants by cross-neutralization indicates that VP7 has at least five overlapping serotype-specific neutralization epitopes which make up a single antigenic site (17a) .
In this study, antigenic analysis of VP7 was extended by preparing several antigenic mutants resistant to anti-VP7 cross-reactive N-MAb YO-4C2 which neutralized HRV strains of serotypes 1, 3, and 4. Moreover, amino acid substitutions in the VP7 responsible for the antigenic alteration in the mutants selected with serotype-specific or crossreactive N-MAbs against HRV were identified.
MATERIALS AND METHODS
Virus. The following 14 a The neutralization titer is expressed as the reciprocal of the highest dilution of ascitic fluid that reduced the fluorescent-focus count by more than 60%.
b The ELISA was carried out by using YO-4C2 ascitic fluid as a capture antibody (22) . ELISA results are shown as the sum of A410 x 1,000 in two wells. Values over 300 in each ELISA test were considered positive.
(serotype 3) were used as parental viruses. A KU antigenic mutant was selected with the KU-4, KU-3C7, KU-5H1, or KU-6A11 anti-VP7 serotype 1-specific N-MAb. Also, KU, P, ST-3, and RRV antigenic mutants were selected with YO-4C2 N-MAb. We used several tubes for each selection as described previously (17a, 20) and isolated two or three independently selected clones for each mutant. Each mutant is designated by a V followed by the name of the N-MAb used for its selection, and the parental virus of each mutant is given in parentheses.
ELISA and neutralization test. An enzyme-linked immunosorbent assay (ELISA) for exatnining the reactivity of NMAbs with virus strains was carried out as described previously (22) . The neutralization test was performed by. a fluorescent-focus reduction or plaque reduction method (13, 23) .
Nucleotide sequence determination. The nucleotide sequence of the VP7 gene of the parent strain and the antigenic mutants was determined by primer extension analysis as described previously (10) .
Preparation of synthetic peptides. $ynthetic peptides were prepared by the solid-phase method with a Beckman 990 peptide synthesizer. An ELISA for examining the reactivity of N-MAbs with synthetic peptides was carried out as follows. Polyvinyl microdilution plates were coated with peptide (5 ,ug per well) overnight at 37°C. After being washed with phosphate-buffered saline containing 0.05% Tween 20, the wells were saturated with 10% fetal calf serum. Aliquots (50 ,ul) of dilutions of ascitic fluid were placed in the wells and incubated for 2 h at 37°C. After being washed with phosphate-buffered saline containing 0.05% Tween 20, the samples were incubated for a futther 2 h with alkaline phosphatase-conjugated goat anti-mouse immunoglobulin G. Finally, 100 ,ul of a p-nitrophenylphosphoric acid disodium salt solution was added. Values over 300 when expressed as the sum of the A405 X 1,000 for two wells were considered positive.
RESULTS
Relationship among serotype-specific and cross-reactive neutralization epitopes on VP7. In our previous study (17a), we characterized five anti-VP7 serotype 1-specific N-MAbs (KU-2, KU-4, KU-3C7, KU-5H1, and KU-6A11) prepared by using strain KU as the immunizing antigen, and we prepared four antigenic mutants (V-KU-4, V-KU-3C7, V-KU-5H1 and V-KU-6A11) selected with the respective NMAbs. In this study we obtained a cross-reactive anti-VP7 N-MAb, YO-4C2, which neutralized HRV strains of serotypes 1, 3, ahd 4 ( Fig. 1 .
Only a single nucleotide change was found on the entire VP7 gene in each mutant. Table 3 shows the nucleotide and deduced amino acid sequence changes in the mutants. Two or three clones independently selected with the same NMAbs were sequenced, and the same amino acid substitution at the same position was obtained for all antigenic mutants except for V-YO-4C2 (KU). V-KU-3C7 (KU) and V-KU-5H1 (KU) sustained a single amino acid substitution at positions 94 (Asn to Ser) and 97 (Asp to Gly), respectively. In V-KU-6A11 (KU) and V-KU-4 (KU) the amino acid substitution occurred at residues 211 (Asn to Asp) and 213 (Asp to Gly), respectively. In contrast, two independently selected KU antigenic mutants, V-YO-4C21 (KU) and V-YO-4C211 (KU), which showed different reactivity patterns with the five serotype 1-specific N-MAbs, differed in the position at which an amino acid substitution occurred; in the first instance it was at position 96 (Gly to Asp), and in the second instance it was at position 99 (Lys to Glu). The P, ST-3, and RRV antigenic mutants selected with the crossreactive YO-4C2 antibody sustained amino acid substitutions at positions 96 (Asn to Asp), 94 (Ser to Asn), and 98 (Trp to Leu), respectively. Thus, all the antigenic mutants selected with N-MAbs had an amino acid substitution in either variable region B (amino acids 87 to 101) or E (amino acids 208 to 221) (9, 10a, 12) .
Reactivity of N-MAbs with synthetic peptides. To examine whether the amino acid substitutions found in the N-MAbselected RV mutants are located inside the binding site of N-MAbs, we examined the reactivity of N-MAb with two synthetic peptides (amino acids 87 to 104 and 204 to 221) corresponding to the amino acid sequence of parental strain KU in the region of the amino acid substitutions found in the mutants (Fig. 1) . However, neither of the synthetic peptides could be recognized by any of the five serotype 1-specific N-MAbs in ELISA (data not shown).
DISCUSSION
Cross-neutralization tests involving five serotype 1-specific N-MAbs and mutants selected with four of the N-MAbs showed that the five serotype 1-specific neutralization epitopes recognized by the N-MAbs were distinct from each other, but overlapped operationally as constituents of a single antigenic site (17a) . Sequence analysis of the antigenic mutants revealed that amino acid substitutions were limited to two variable regions on VP7, B (amino acids 87 to 101) and E (amino acids 208 to 221) (9, 10a, 12) . These results suggest that these two regions of VP7, B and E, are in close proximity in the three-dimensional structure of VP7, although they are widely separated in the linear sequence. Our observations with an HRV serotype 1 strain are similar to those previously reported by Dyall-Smith et al. for a simian RV serotype 3 strain (SA-11) (7). Accordingly, it appears that immunodominant neutralization epitopes of VP7 are located on the same site in viruses of different serotypes as well as different host species of origin. It is of interest that the amino acid substitutions found in the antigenic mutants resistant to serotype-specific N-MAbs (serotype 1 [KU] and serotype 3 [SA-11]) yielded aspartic acid and asparagine in most instances (7) .
It is of interest that the antigenic mutants developed amino acid substitutions which corresponded to amino acids For example, with regard to V-KU-3C7 (KU), the amino acid (Asn) at residue 94 of the parent KU strain was replaced by Ser, which is the residue at the corresponding position of RV serotypes 2 and 4 (10a), and V-KU-6A11 (KU) underwent an amino acid substitution at position 211 from Asn to Asp, the latter being the amino acid in this position in serotypes 2, 3, and 5 (10a). These observations suggest that there are constraints governing which amino acids can be tolerated in specific positions in the functional VP7. Heterotypic protective immunity has been observed following RV infection, but this has not been a consistent finding (2, 8, 15, 18, 24, 25) . An understanding of the viral determinants responsible for eliciting such heterotypic protective immunity is fundamental to the construction of an effective RV vaccine. In previous studies (20) , we demonstrated that VP3 has at least three cross-reactive neutralization epitopes. Furthermore, recently, the location of the cross-reactive neutralization epitopes was identified, at the molecular level, by sequencing the VP3 genes of the anti- This indicates that VP7 also possesses cross-reactive neutralization epitopes. Unexpectedly, cross-neutralization tests between six N-MAbs including the cross-reactive YO-4C2 antibody and antibody-selected antigenic mutants showed that the cross-reactive neutralization epitope recognized by YO-4C2 antibody was located within variable region B, which also contains serotype-specific neutralization epitopes. The KU antigenic mutants resistant to YO-4C2 antibody had an amino acid substitution at position 96 or 99, depending on the mutant analyzed. Similarly, the P, ST-3, and RRV antigenic mutants resistant to YO-4C2 antibody sustained an amino acid substitution in the same region: 96 (Asn to Asp), 94 (Ser to Asn), and 98 (Trp to Leu), respectively.
Sequence analysis of the VP7 gene of antigenic mutants selected with serotype-specific or cross-reactive N-MAbs allowed us to identify the amino acid substitution responsible for the antigenic alteration of each mutant. However, the position of an amino acid substitution does not necessarily correspond to the actual binding site of the N-MAb. For example, most amino acid substitutions found in the NMAb-selected poliovirus type 1 mutants were located outside the binding site of N-MAb, whereas all mutations of poliovirus type 3 were found to cluster between amino acids 93 and 100 of VP1, which is the N-MAb-binding site (1, 6, 17) . In this study, the failure of reactivity of N-MAbs with synthetic peptides corresponding to the amino acid sequence in the region of amino acid substitutions found in the RV mutants may suggest that the regions of amino acid substitutions found in the RV mutants are outside the N-MAbbinding site. Alternatively, the regions form the conformational antigenic site which resulted in the failure of recognition by N-MAbs, even if the positions of amino acid substitutions are located inside the N-MAb-binding site.
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